Evelo Biosciences to Report Second Quarter 2021 Financial Results on Thursday, July 29, 2021
Evelo Biosciences (Nasdaq:EVLO) announced a conference call scheduled for July 29, 2021, at 8:30 a.m. ET to discuss its second quarter 2021 financial results and business highlights. The call can be accessed by dialing 866-795-3242 (domestic) or 409-937-8909 (international), using conference ID 1658301. A live webcast will also be available on Evelo's website, and an archived version will be accessible for 30 days post-event.
Evelo is focused on developing orally delivered medicines targeting the small intestinal axis, with four product candidates aimed at inflammatory diseases and cancer.
- Evelo Biosciences has four product candidates in development for inflammatory diseases and cancer.
- The company's innovative approach focuses on orally delivered medicines, potentially broadening treatment options.
- None.
CAMBRIDGE, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, July 29, 2021, to report its second quarter 2021 financial results and discuss business highlights.
To access the live conference call, please dial 866-795-3242 (domestic) or 409-937-8909 (international) and refer to conference ID 1658301. A live webcast of the event will also be available under “News and Events” in the Investors section of Evelo's website at http://ir.evelobio.com. The archived webcast will be available on Evelo's website approximately two hours after the completion of the event and will be available for 30 days following the call.
About Evelo Biosciences
Evelo Biosciences is a clinical stage biotechnology company developing orally delivered medicines that act on the small intestinal axis, SINTAX™, to have systemic therapeutic effects. SINTAX plays a central role in governing the immune, metabolic, and neurological systems.
Evelo currently has four product candidates in development: EDP1815, EDP1867, and EDP2939 for the treatment of inflammatory diseases and EDP1908 for the treatment of cancer. Evelo is advancing additional product candidates in other disease areas.
For more information, please visit www.evelobio.com and engage with Evelo on LinkedIn.
Contact
Jessica Cotrone, 978-760-5622
jcotrone@evelobio.com
FAQ
When will Evelo Biosciences report its second quarter 2021 financial results?
How can I access the Evelo Biosciences conference call?
What is Evelo's focus in drug development?
